LTI-291

CAS : 1919820-28-2

Ref. 3D-UBD82028

Informations sur le produit

• Nom: LTI-291
• CAS: 1919820-28-2

Description

LTI-291 is a cholesterol synthesis inhibitor that stabilizes the membrane by inhibiting the cholesterol homeostasis. LTI-291 has been shown to inhibit the biosynthesis of cholesterol, which leads to an increase in the number of cells with low or zero levels of cholesterol. This drug also inhibits HMG-CoA reductase, an enzyme that catalyzes reactions in the mevalonate pathway and is involved in lipid and sterol synthesis. The reduced production of cholesterol leads to a decrease in its concentration within myocardial cells. LTI-291 has been shown to be effective in animal studies as well as clinical trials on humans. It is currently undergoing phase III clinical trials for its use in preventing atherosclerosis.

LTI 291 inhibits cholesterol synthesis by stabilizing cells and inhibiting HMG-CoA reductase, an enzyme involved in lipid and sterol synthesis which leads to a decrease in its concentration within myocardial cells.br>
LTI

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 358.48 g/mol
• Formule: C₂₀H₃₀N₄O₂
• Degré de pureté: Min. 95%